VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: August 31, 2022

VALNEVA - Declaration of shares and voting rights: August 31, 2022

VALNEVA

Declaration of shares and voting rights

August 31, 2022

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment A

Declaration date: September 5, 2022

  

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



117,351,857



 



    including:
  • 117,331,343 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
139,906,042Sale of 450 shares with double voting rights



 



Double voting rights granted on 3,126 ordinary shares



 
August 4 & 12, 2022



 



August 17 & 25, 2022
139,781,720

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.



Attachment



EN
05/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Ind...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older Saint Herblain (France), August 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252. In addit...

 PRESS RELEASE

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé ...

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus Saint-Herblain (France), le 18 août 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à dose unique, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya chez les personnes âgées de 12 ans et plus. Cette annonce s'ajoute à l'autorisation de mise sur le marché déjà obtenue au Canada pour les adultes1 et fait...

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch